Publications in collaboration with researchers from Hospital Miguel Servet (19)

2019

  1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635

2018

  1. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study

    Investigational New Drugs, Vol. 36, Núm. 3, pp. 468-475

  2. SEOM clinical guideline on unknown primary cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 89-96

  3. SEOM clinical guidelines in gestational trophoblastic disease (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 38-46

2015

  1. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

    Annals of Surgical Oncology, Vol. 22, Núm. 9, pp. 2948-2957

2014

  1. Impact of the lymphadenectomy in high-risk histologic types of endometrial cancer: A matched-pair study

    International Journal of Gynecological Cancer, Vol. 24, Núm. 4, pp. 703-712

2011

  1. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish group for research on sarcomas study

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2528-2533

  2. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study

    Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 55, Núm. 6, pp. 680-687

2010

  1. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: A phase I-II study by the Spanish group for research on sarcomas

    Cancer, Vol. 116, Núm. 15, pp. 3692-3701

  2. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer

    Anticancer Research, Vol. 30, Núm. 6, pp. 2255-2261

  3. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1552-1557

2006

  1. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study

    British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802

2005

  1. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: A study by the spanish group for research on sarcomas

    Cancer, Vol. 104, Núm. 8, pp. 1706-1712

  2. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Annals of Oncology, Vol. 16, Núm. 5, pp. 749-755

2004

  1. Salvage surgical resection after High-Dose Ifosfamide (HDIF) based regimens in Advanced Soft Tissue Sarcoma (ASTS): A potential positive selection bias - A study of the Spanish group for research on sarcomas (GEIS)

    Journal of Surgical Oncology, Vol. 88, Núm. 1, pp. 44-49

  2. Sequential Dose-Dense Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcomas: A Phase II Trial by the Spanish Group for Research on Sarcomas (GEIS)

    Cancer, Vol. 100, Núm. 7, pp. 1498-1506

2003

  1. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: A Cooperative Study by the GEICAM Group

    Clinical Breast Cancer, Vol. 3, Núm. 6, pp. 399-404

1998

  1. Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Annals of Oncology, Vol. 9, Núm. 7, pp. 783-785

  2. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Annals of Oncology, Vol. 9, Núm. 8, pp. 871-876